Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

18.72 +0.33 (+1.79%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Limited - American Depositary Shares

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 02, 2022

Gainers Trevi Therapeutics (NASDAQ:TRVI) shares rose 46.6% to $1.28 during Wednesday's regular session. As of 12:30 EST, Trevi Therapeutics's stock is trading at a...

Via Benzinga

41 Stocks Moving In Wednesday's Mid-Day Session ↗

March 02, 2022

Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday. Nordstrom, Inc. (NYSE: JWN) shares jumped 38.7% to $27.11 after the company reported...

Via Benzinga

Recap: Zai Lab FY Earnings ↗

March 01, 2022

Zai Lab (NASDAQ:ZLAB) reported its FY earnings results on Tuesday, March 1, 2022 at 04:30 PM. Here's what investors need to know about the announcement. Earnings Zai Lab...

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

January 18, 2022

Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a...

Via Benzinga

A Preview Of Zai Lab's Earnings ↗

February 28, 2022

Zai Lab (NASDAQ:ZLAB) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate...

Via Benzinga

The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More ↗

January 23, 2022

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that...

Via Talk Markets

The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More ↗

January 23, 2022

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the...

Via Benzinga

Promising Developments in Breast Cancer Treatments Ahead in 2022

January 12, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against...

Via FinancialNewsMedia

Argenx's Vyvgart Wins FDA Approval For Autoimmune, Neuromuscular Disease ↗

December 20, 2021

The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart (efgartigimod alfa-fcab) for generalized myasthenia gravis (gMG) in adult patients who are anti-...

Via Benzinga

Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board ↗

December 18, 2021

BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai.

Via Talk Markets

58 Biggest Movers From Yesterday ↗

December 17, 2021

Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price...

Via Benzinga

Mid-Afternoon Market Update: Nasdaq Down 2.5%; Calliditas Therapeutics Shares Spike Higher ↗

December 16, 2021

Toward the end of trading Thursday, the Dow traded up 0.05% to 35,946.32 while the NASDAQ fell 2.5% to 15,179.38. The S&P also fell, dropping 0.80% to 4,672.38. The U.S. has...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

December 16, 2021

Gainers Calliditas Therapeutics (NASDAQ:CALT...

Via Benzinga

31 Stocks Moving In Thursday's Mid-Day Session ↗

December 16, 2021

Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce...

Via Benzinga

The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗

December 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...

Via Benzinga

Zai Lab's Nuzyra Approved In China For Bacterial Infections ↗

December 16, 2021

The China National Medical Products Administration (NMPA) has approved Zai Lab Limited's (NASDAQ: ZLAB) Nuzyra (omadacycline), a novel antibiotic with both oral...

Via Benzinga

46 Biggest Movers From Yesterday ↗

December 16, 2021

Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 15, 2021

Gainers Biofrontera (NASDAQ:

Via Benzinga

36 Stocks Moving In Wednesday's Mid-Day Session ↗

December 15, 2021

Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal...

Via Benzinga

Mid-Morning Market Update: Markets Open Lower; US Retail Sales Miss Estimates ↗

December 15, 2021

Following the market opening Wednesday, the Dow traded down 0.26% to 35,453.17 while the NASDAQ fell 0.62% to 15,142.70. The S&P also fell, dropping 0.28% to 4,621.34. The U.S...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates ↗

December 02, 2021

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for...

Via Benzinga

Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million ↗

November 13, 2021

Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics.

Via Talk Markets

Why Karuna Therapeutics Stock Tumbled This Week ↗

November 12, 2021

Investors apparently weren't thrilled by the company's licensing agreement with Zai Lab.

Via The Motley Fool

Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates ↗

November 09, 2021

Zai Lab Limited (NASDAQ: ZLAB) and Blueprint Medicines Corporation (NASDAQ: BPMC) have announced an exclusive collaboration and license agreement in...

Via Benzinga

PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

November 09, 2021

From PureTech Health plc

Via Business Wire

Earnings Scheduled For November 9, 2021 ↗

November 09, 2021

Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings...

Via Benzinga

Week In Review: China's Hansoh Signs Two siRNA Deals Worth $1.7 Billion ↗

October 23, 2021

Hansoh announced a $1.3 billion deal to develop three siRNA candidates from London's Silence Therapeutics. In the past week, Hansoh also revealed a $456 million deal with Korea's OliX Pharma for China...

Via Talk Markets

Zai Lab Posts Encouraging Data From Early-Stage Plaque Psoriasis Trial ↗

October 21, 2021

Zai Lab Limited (NASDAQ: ZLAB) announced topline results from Phase 1b study of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque...

Via Benzinga

Crescendo Biologics Announces That Zai Lab Has Achieved Proof-of-Concept for ZL-1102 (Humabody®, CB001) in a Phase 1b Clinical Trial in Psoriasis Patients

October 21, 2021

From Crescendo Biologics Ltd

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

All News about Zai Lab Limited - American Depositary Shares